Thomas F. Dejgaard
About
Thomas F. Dejgaard is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology.
According to data from OpenAlex, Thomas F. Dejgaard has authored 35 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Surgery and 6 papers in Molecular Biology. Recurrent topics in Thomas F. Dejgaard's work include Diabetes Management and Research (28 papers), Diabetes Treatment and Management (27 papers) and Pancreatic function and diabetes (17 papers). Thomas F. Dejgaard is often cited by papers focused on Diabetes Management and Research (28 papers), Diabetes Treatment and Management (27 papers) and Pancreatic function and diabetes (17 papers). Thomas F. Dejgaard collaborates with scholars based in Denmark, United States and Iceland. Thomas F. Dejgaard's co-authors include Sten Madsbad, Christian S. Frandsen, Henrik U. Andersen, Jens J. Holst, Filip K. Knop, Birger Thorsteinsson, Lise Tarnow, Ulrik Pedersen‐Bjergaard, Tina Vilsbøll and Thomas Almdal and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Diabetes Care and Diabetes.
In The Last Decade
Thomas F. Dejgaard
34 papers receiving 813 citations
Peers
Thomas F. Dejgaard
Gerlies Bock United States
Hitoshi Kuwata Japan
Enrique Romero Spain
Silvia Magno Italy
M. Traversa Italy
Sri Prakash Mokshagundam United States
Amy Baumgartner United States
Ae. Lambert Belgium
Antonio Rossi Italy
Xiaofei Su China
Citations per year, relative to Thomas F. Dejgaard Thomas F. Dejgaard (= 1×)
peers
Gerlies Bock
Countries citing papers authored by Thomas F. Dejgaard
Since
Specialization
Citations
This map shows the geographic impact of Thomas F. Dejgaard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Dejgaard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Dejgaard more than expected).
Fields of papers citing papers by Thomas F. Dejgaard
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Thomas F. Dejgaard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Dejgaard. The network helps show where Thomas F. Dejgaard may publish in the future.
Co-authorship network of co-authors of Thomas F. Dejgaard
This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Dejgaard. A scholar is included among the top collaborators of Thomas F. Dejgaard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Dejgaard. Thomas F. Dejgaard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dejgaard, Thomas F., Christian S. Frandsen, Urd Kielgast, et al.. (2024). Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double‐blind, placebo‐controlled trial. Diabetes Obesity and Metabolism. 26(11). 4905–4915.
2.
Bergmann, Natasha C., Bolette Hartmann, Jens J. Holst, et al.. (2021). The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. Diabetologia. 64(11). 2425–2431.
3.
Dejgaard, Thomas F., Bernt Johan von Scholten, Erik Christiansen, et al.. (2021). Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials. Diabetes Obesity and Metabolism. 23(12). 2752–2762.
4.
Færch, Kristine, Martin Bæk Blond, Hanan Amadid, et al.. (2020). The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial. Diabetologia. 64(1). 42–55.
5.
Dejgaard, Thomas F., Asger Lund, Christian S. Frandsen, et al.. (2020). Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 8(4). 313–324.
6.
Bergmann, Natasha C., Bolette Hartmann, Jens J. Holst, et al.. (2020). 351-OR: Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes. Diabetes. 69(Supplement_1).
7.
Hansen, Christian Stevns, Christian S. Frandsen, Jesper Fleischer, et al.. (2019). Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology. 10. 242–242.
8.
Dejgaard, Thomas F., et al.. (2018). Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. BMJ Open. 8(6). e021861–e021861.
9.
Østergaard, Lauge, Ulrik M. Mogensen, Johan Skov Bundgaard, et al.. (2018). Duration and complications of diabetes mellitus and the associated risk of infective endocarditis. International Journal of Cardiology. 278. 280–284.
10.
Østergaard, Lauge, Christian S. Frandsen, Thomas F. Dejgaard, & Sten Madsbad. (2017). Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes. Expert Review of Clinical Pharmacology. 10(6). 621–632.
11.
Fleischer, Jesper, Esben Laugesen, Simon Lebech Cichosz, et al.. (2017). Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy. Journal of Diabetes and its Complications. 31(9). 1389–1393.
12.
Kelstrup, Louise, Thomas F. Dejgaard, Tine D. Clausen, et al.. (2016). Levels of the inflammation marker YKL-40 in young adults exposed to intrauterine hyperglycemia. Diabetes Research and Clinical Practice. 114. 50–54.
13.
Dejgaard, Thomas F., Christian S. Frandsen, Jens J. Holst, & Sten Madsbad. (2016). Liraglutide for treating type 1 diabetes. Expert Opinion on Biological Therapy. 16(4). 579–590.
14.
Dejgaard, Thomas F., Nanna B. Johansen, Christian S. Frandsen, et al.. (2016). Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes Obesity and Metabolism. 19(5). 734–738.
15.
Frandsen, Christian S., Thomas F. Dejgaard, & Sten Madsbad. (2016). Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus. The Lancet Diabetes & Endocrinology. 4(9). 766–780.
16.
Frandsen, Christian S., Thomas F. Dejgaard, Henrik U. Andersen, et al.. (2016). Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo‐controlled, double‐blind, parallel‐group study. Diabetes Obesity and Metabolism. 19(6). 773–782.
17.
Dejgaard, Thomas F., Christian S. Frandsen, Tanja Sofie Hansen, et al.. (2015). Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 4(3). 221–232.
18.
Dejgaard, Thomas F., Filip K. Knop, Lise Tarnow, et al.. (2015). Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open. 5(4). e007791–e007791.
19.
Frandsen, Christian S., Thomas F. Dejgaard, Jens J. Holst, et al.. (2015). Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study. Diabetes Care. 38(12). 2250–2257.
20.
Winding, Kamilla, Anders R. Nielsen, Thomas F. Dejgaard, et al.. (2013). Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy. Endocrine Related Cancer. 20(5). 621–632.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gerlies Bock Breakdown of academic impact, for papers by Hitoshi Kuwata Breakdown of academic impact, for papers by Enrique Romero Breakdown of academic impact, for papers by Silvia Magno Breakdown of academic impact, for papers by M. Traversa Breakdown of academic impact, for papers by Sri Prakash Mokshagundam Breakdown of academic impact, for papers by Amy Baumgartner Breakdown of academic impact, for papers by Ae. Lambert Breakdown of academic impact, for papers by Antonio Rossi Breakdown of academic impact, for papers by Xiaofei Su